Submissions from 2021
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy, Keith Sadoon Bahjat, Helena Maria Hoen, Yoshinobu Koguchi, and Alan J. Korman
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy, Keith Sandoon Bahjat, Helena Maria Hoen, Yoshinobu Koguchi, and Alan J. Korman
Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Neil Bailey, Tenzin Tsomo, Tori Braun, Jennie Szeto, William Bensinger, Daniel N Egan, Raya Mawad, Livia Hegerova, Gayle Funk, Joanna Fesler, Megumi Bailey, John M Pagel, and Krish Patel
Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy., Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K Chan, John W Kappler, Yu Zhou, Eric Tran, Philippa Marrack, and Lei Yin
Prevalence and Correlates of Successful Smoking Cessation in Bladder Cancer Survivors., Jeffrey C Bassett, Richard S Matulewicz, Lorna Kwan, William J McCarthy, John L Gore, and Christopher S Saigal
A national database propensity score-matched comparison of minimally invasive and open colectomy for long-term opioid use., Amir L Bastawrous, Kara K Brockhaus, Melissa I Chang, Gediwon Milky, I-Fan Shih, Yanli Li, and Robert K Cleary
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response., Joshua Bauml, Byoung Chul Cho, Rachel E Sanborn, and See full author list in comments
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update., Nancy N Baxter, Erin B Kennedy, Emily Bergsland, Jordan Berlin, Thomas J George, Sharlene Gill, Philip J Gold, Alex Hantel, Lee Jones, Christopher Lieu, Najjia Mahmoud, Arden M Morris, Erika Ruiz-Garcia, Y Nancy You, and Jeffrey A Meyerhardt
Identifying breast cancer recurrence histories via patient-reported outcomes., J David Beatty, Qin Sun, Daniel Markowitz, Jessica Chubak, Bin Huang, and Ruth Etzioni
The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer., Anil Belur Nagaraj, Matthew Knarr, Sreeja Sekhar, R Shae Connor, Peronne Joseph, Olga Kovalenko, Alexis Fleming, Arshia Surti, Elmar Nurmemmedov, Luca Beltrame, Sergio Marchini, Michael Kahn, and Analisa DiFeo
The virtual molecular tumor board as a tool for the delivery of precision oncology, Carlo Bifulco
10. Dendritic cell migration is required for the immunological responsiveness of tumors to radiation therapy, TC Blair, G Kramer, S Bambina, A Dowdell, AF Alice, Brian D. Piening, Marka R Crittenden, and MJ Gough
Minimally invasive esophagectomy., Adam J Bograd and Daniela Molena
Salvage Pulmonary Resections After Definitive Chemoradiotherapy., Adam J Bograd and Eric Vallieres
DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategies., Alipi Bonm and Santosh Kesari
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data., Daniela A Bota, Warren Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Ileana Elias, Steven D Reich, Nancy Levin, Mohit Trikha, and Annick Desjardins
Impact of rurality on melanoma diagnosis in Utah., Tawnya L Bowles, Carol Sweeney, John Snyder, Jesse Gygi, Brad Bott, Daniel Wray, Timothy J Yeatman, and William T Sause
Merkel cell carcinoma can be indolent: A case with 7 locoregional recurrences over 15 years highlights the importance of patient-tailored management., Alyssa Breneman, Tomoko Akaike, Kelly G Paulson, Debra L Breneman, and Paul Nghiem
165 Generating enhanced tumor infiltrating lymphocytes through microfluidic cell squeezing, Devin Bridgen, Andrew D Weinberg, and See full list of authors in comments
A Randomized Study of Lenvatinib 18 mg Vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer., Marcia S Brose, Yury Panaseykin, Bhavana Konda, Christelle de La Fouchardiere, Brett G M Hughes, Andrew G Gianoukakis, Young Joo Park, Ilia Romanov, Monika K Krzyzanowska, Sophie Leboulleux, Terri A Binder, Corina Dutcus, Ran Xie, and Matthew H Taylor
Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry., Daniel Brown, Henry Krebs, Jayson Brower, Ryan O'Hara, Eric Wang, Kirubahara Vaheesan, Liping Du, Lea Matsuoka, Donna D'Souza, Daniel Y Sze, Jafar Golzarian, Ripal Gandhi, and Andrew Kennedy
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients., Jennifer R Brown, John C Byrd, Paolo Ghia, Jeff P Sharman, Peter Hillmen, Deborah M Stephens, Clare Sun, Wojciech Jurczak, John M Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, and Richard R Furman
Imaging Administrators: The Overlooked Barrier to Lung Cancer Screening Implementation., Kerrie E Buehler, Candice L. Wilshire, Christopher R Gilbert, and Jed A Gorden
A case of metachronous bilateral secretory carcinoma., Jessica Burlile, Andrea Collins, Joaquin Garcia, Kristin Gendron, Danielle Cunningham, and Robert Foote
The benefits of fasting for patients who are immunocompromised and undergoing cancer treatment: An integrative research review, Lori Burnett
A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors., Howard A. Burris III, Alexander I. Spira, and Matthew H Taylor
Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia., John C Byrd, Jennifer A Woyach, Richard R Furman, Peter Martin, Susan O'Brien, Jennifer R Brown, Deborah M Stephens, Jacqueline Barrientos, Stephen Devereux, Peter Hillmen, John M Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, and William George Wierda
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells., Danda Chapagai, Gurusankar Ramamoorthy, Jessy Varghese, Elmar Nurmemmedov, Campbell McInnes, and Michael D Wyatt
Portable air-fed cold atmospheric plasma device for postsurgical cancer treatment., Guojun Chen, Zhitong Chen, Zejun Wang, Richard Obenchain, Di Wen, Hongjun Li, Richard E Wirz, and Zhen Gu
Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population-based study., Leo Chen, Caroline H Speers, Winson Y Cheung, John J Spinelli, and Hagen F Kennecke
Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial., K Kent Chevli, Neal D Shore, Andrew Trainer, Angela B Smith, Daniel Saltzstein, Yaron Ehrlich, Jay D Raman, Boris Friedman, Richard D'Anna, David Morris, Brian Hu, Mark Tyson, Alexander Sankin, Max Kates, Jennifer Linehan, Douglas Scherr, Steven Kester, Michael Verni, Karim Chamie, Lawrence Karsh, Arnold Cinman, Andrew Meads, Soumi Lahiri, Madlen Malinowski, Nimrod Gabai, Sunil Raju, Mark Schoenberg, Elyse Seltzer, and William C Huang
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer., R Connor Chick, G Travis Clifton, Diane F Hale, Timothy J Vreeland, Annelies T Hickerson, Phillip M Kemp Bohan, Patrick M McCarthy, Jennifer K Litton, Gheath Alatrash, Rashmi K Murthy, Na Qiao, Anne Philips, Jason Lukas, Jarrod P Holmes, Elizabeth A Mittendorf, and George E Peoples
Undifferentiated Carcinoma With Osteoclast-Like Giant Cells of the Pancreas Discovered on Positron Emission Tomography Performed for Lymphoma Staging., Wade O Christopher, Trevan D Fischer, and Anton J Bilchik
SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology., Ugonma N Chukwueke, Elizabeth Vera, Alvina Acquaye, Shawn L Hervey-Jumper, Yazmin Odia, Laura J Klesse, Erin Dunbar, Akanksha Sharma, Ekokobe Fonkem, Alissa A Thomas, Tamra E Werbowetski-Ogilvie, Sandra Camelo-Piragua, Na Tosha N Gatson, Macarena I de la Fuente, Terri S Armstrong, Alyx B Porter, and Sadhana Jackson
P2-14-07. Marrow-infiltrating lymphocytes as adoptive immunotherapy for breast cancer, Brie Chun, Nicole E. Fredich, David B Page, and See all authors in comments
94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC), Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather McArthur, and David B Page
Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC), Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather McArthur, and David B Page
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2, Amy S Clark, Christina Yau, Denise M Wolf, Emanuel F Petricoin, Laura J van 't Veer, Douglas Yee, Stacy L Moulder, Anne M Wallace, A Jo Chien, Claudine Isaacs, Judy C Boughey, Kathy S Albain, Kathleen Kemmer, Barbara B Haley, Hyo S Han, Andres Forero-Torres, Anthony Elias, Julie E Lang, Erin D Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher, Teresa Helsten, Erin Roesch, Cheryl A Ewing, Michael Alvarado, Erin P Crane, Meredith Buxton, Julia L Clennell, Melissa Paoloni, Smita M Asare, Amy Wilson, Gillian L Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S Rugo, Richard B Schwab, W Fraser Symmans, Nola M Hylton, Donald A Berry, Laura J Esserman, and Angela M DeMichele
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2., Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, and Janice P Dutcher
Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings., Roger B. Cohen, George E. Peoples, Rachel E Sanborn, and See list of authors in comments
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors., Kevin Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William D Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati Gupta, Rom Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, and George N Pavlakis
Implementation of human papillomavirus video education for women participating in mass cervical cancer screening in Tanzania., Emma C Cooper, Justine A Maher, Ariana Naaseh, Elizabeth W Crawford, Justine O Chinn, Ava S Runge, Alexa N Lucas, Danielle C Zezoff, Kevin R Bera, Andreea I Dinicu, Kayla M White, Sujata E Tewari, Anjali Hari, Megan Bernstein, Jenny Chang, Argyrios Ziogas, Diana C Pearre, and Krishnansu S Tewari
Combinations of stereotactic radiotherapy and immune checkpoint inhibition: Translational analyses, Marka R Crittenden
Integrating Radiation Therapy with Immunotherapy, Marka R Crittenden
My surgical practice: Presenting aesthetic flat closure as an equal option to mastectomy with reconstruction and technical considerations to optimize cosmesis., Angelena Crown and Claire Buchanan
Recent Advances in the Treatment of Melanoma., Brendan D Curti and Mark B Faries
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor., Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady Bernard, Ian Hilgart-Martiszus, Christopher B Fountain, George Morris, Noriko Iwamoto, Takashi Shimada, ShuChing Chang, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin, and William L Redmond
381 Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study, Brendan Curti and See full list of authors in comments
Laboratory and Clinical Implications of Incidental and Secondary Germline Findings During Tumor Testing., Allison Cushman-Vokoun, Josh Lauring, John Pfeifer, Damon R Olson, Anna Berry, John Thorson, Karl Voelkerding, Jonathan Myles, James Barbeau, Pranil Chandra, Marilyn Li, Gail H Vance, Brad W Jensen, Molly Y Hansen, and Sophia Yohe
Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19., Felice D'Agnillo, Kathie-Anne Walters, Yongli Xiao, Zong-Mei Sheng, Kelsey Scherler, Jaekeun Park, Sebastian Gygli, Luz Angela Rosas, Kaitlyn Sadtler, Heather Kalish, Charles A Blatti, Ruoqing Zhu, Lisa Gatzke, Colleen Bushell, Matthew J Memoli, Steven O'Day, Trevan Fischer, Terese C Hammond, Raymond C Lee, J Christian Cash, Matthew E Powers, Grant E O'Keefe, Kelly J Butnor, Amy V Rapkiewicz, William D Travis, Scott P Layne, John C Kash, and Jeffery K Taubenberger
Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis., Paulo D'Amora, Ismael Dale C G Silva, Krishnansu S Tewari, Robert E Bristow, Fabio Cappuccini, Steven S Evans, Marcia B Salzgeber, Paula J Addis-Bernard, Anton M Palma, Dirce M L Marchioni, Antonio A F Carioca, Kristine R Penner, Jill Alldredge, Teresa Longoria, and Robert A Nagourney
Correction to: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling., Christopher Dardis, David Donner, Nader Sanai, Joanne Xiu, Sandeep Mittal, Sharon K Michelhaugh, Manjari Pandey, Santosh Kesari, Amy B Heimberger, Zoran Gatalica, Michael W Korn, Ashley L Sumrall, and Surasak Phuphanich
Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling., Christopher Dardis, David Donner, Nader Sanai, Joanne Xiu, Sandeep Mittal, Sharon K Michelhaugh, Manjari Pandey, Santosh Kesari, Amy B Heimberger, Zoran Gatalica, Michael W Korn, Ashley L Sumrall, and Surasak Phuphanich
Double-blind, randomized placebo-controlled trial of 8-week self-administered at-home behavioral skills-based virtual reality (VR) for chronic low back pain (during COVID-19)., Beth Darnall, Laura Garcia, Brandon Birckhead, Parthasarathy Krishnamurthy, Ian Mackey, Josh Sackman, Robert Louis, and Todd Maddox
Clinical Utility of, Jeeban P Das, Hebert A Vargas, Soleen Ghafoor, Alvin C Goh, and Gary A Ulaner
474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress), Diwakar Davar, Rachel E Sanborn, and See full list of authors in comments
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies., Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S Fenske, Pier Luigi Zinzani, Manish R Patel, Nilanjan Ghosh, Bruce D Cheson, Enrico Derenzini, Danielle M Brander, James A Reeves, Wanda Knopinska-Posluszny, John N Allan, Tycel Phillips, Paolo F Caimi, Ewa Lech-Maranda, John M Burke, Richy Agajanian, Ruth Pettengell, Lori A Leslie, Chan Y Cheah, Gustavo Fonseca, James H Essell, Julio C Chavez, John M Pagel, Jeff P Sharman, Yanzhi Hsu, Hari P Miskin, Peter Sportelli, Michael S Weiss, and Ian W Flinn
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?, Sandra Demaria, Chandan Guha, Jonathan Schoenfeld, Zachary Morris, Arta Monjazeb, Andrew Sikora, Marka Crittenden, Stephen Shiao, Samir Khleif, Seema Gupta, Silvia Chiara Formenti, Bhadrasain Vikram, C Norman Coleman, and Mansoor M Ahmed
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia., Pinkal M Desai, Janice Brown, Saar Gill, Melham M Solh, Luke P Akard, Jack W Hsu, Celalettin Ustun, Charalambos Andreadis, Olga Frankfurt, James M Foran, John Lister, Gary J Schiller, Matthew J Wieduwilt, John M Pagel, Patrick J Stiff, Delong Liu, Irum Khan, Wendy Stock, Suman Kambhampati, Martin S Tallman, Lawrence Morris, John Edwards, Iskra Pusic, Hagop M Kantarjian, Richard Mamelok, Alicia Wong, Rodney Van Syoc, Lois Kellerman, Swapna Panuganti, Ramkumar Mandalam, Camille N Abboud, and Farhad Ravandi
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma., Adi Diab, Scott S Tykodi, Gregory A Daniels, Michele Maio, Brendan D Curti, Karl D Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander I Spira, Daniel C Cho, Shanhong Guan, Erika Puente, Tuan Nguyen, Ute Hoch, Sue L Currie, Wei Lin, Mary A Tagliaferri, Jonathan Zalevsky, Mario Sznol, and Michael E Hurwitz
Disparities in Amputation Rates for Non-metastatic Extremity Soft Tissue Sarcomas and the Impact on Survival., Joshua C Dilday, Daniel W Nelson, Trevan D Fischer, and Melanie Goldfarb
Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity., Phuong Doan, Phung Nguyen, Akshaya Murugesan, Nuno R Candeias, Olli Yli-Harja, and Meenakshisundaram Kandhavelu
Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth., Phuong Doan, Phung Nguyen, Akshaya Murugesan, Kumar Subramanian, Saravanan Konda Mani, Vignesh Kalimuthu, Bobin George Abraham, Brett W Stringer, Kadalmani Balamuthu, Olli Yli-Harja, and Meenakshisundaram Kandhavelu
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors., Khanh T Do, Laura Quan Man Chow, Karen Reckamp, Rachel E Sanborn, Howard Burris, Francisco Robert, D Ross Camidge, Conor E Steuer, John H Strickler, Amy Weise, Jennifer M Specht, Martin Gutierrez, Peter Haughney, Shawna Hengel, Christina Louise Derleth, and Timothy A Yap
Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up., Charles W Drescher, Adam J Bograd, Shu-Ching Chang, Roshanthi Weerasinghe, Ann Vita, and Richard Bryan Bell
Effect of Use of a Bougie vs Endotracheal Tube With Stylet on Successful Intubation on the First Attempt Among Critically Ill Patients Undergoing Tracheal Intubation: A Randomized Clinical Trial., Brian E Driver, Matthew W Semler, Wesley H Self, Adit A Ginde, Stacy A Trent, Sheetal Gandotra, Lane M Smith, David B Page, Derek J Vonderhaar, Jason R West, Aaron M Joffe, Steven H Mitchell, Kevin C Doerschug, Christopher G Hughes, Kevin High, Janna S Landsperger, Karen E Jackson, Michelle P Howell, Sarah W Robison, John P Gaillard, Micah R Whitson, Christopher M Barnes, Andrew J Latimer, Vikas S Koppurapu, Bret D Alvis, Derek W Russell, Kevin W Gibbs, Li Wang, Christopher J Lindsell, David R Janz, Todd W Rice, Matthew E Prekker, Jonathan D Casey, and BOUGIE Investigators and the Pragmatic Critical Care Research Group
The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation., Shaan Dudani, Horia Marginean, Joanna Gotfrit, Patricia A Tang, Jose Gerard Monzon, Kristopher Dennis, Hagen F Kennecke, Erin D Powell, Sam Babak, Winson Y Cheung, and Michael M Vickers
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells., Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo Bifulco, Brady Bernard, Rom Leidner, Brendan Curti, Bernard A Fox, Walter Urba, Richard Bryan Bell, and Andrew D Weinberg
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial., R Dummer, D E Gyorki, J Hyngstrom, A C Berger, R Conry, L Demidov, A Sharma, S A Treichel, H Radcliffe, K S Gorski, A Anderson, E Chan, M Faries, and M I Ross
Cabozantinib: An evolving therapy for hepatocellular carcinoma., Anthony B El-Khoueiry, Diana L Hanna, Josep Llovet, and Robin Kate Kelley
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma., Benjamin M Ellingson, John Sampson, Achal Singh Achrol, Manish K Aghi, Krystof Bankiewicz, Chencai Wang, Martin Bexon, Steven Brem, Andrew Brenner, Sajeel Chowdhary, John R Floyd, Seunggu Han, Santosh Kesari, Dina Randazzo, Michael A Vogelbaum, Frank Vrionis, Miroslaw Zabek, Nicholas Butowski, Melissa Coello, Nina Merchant, and Fahar Merchant
Cryopreserved placental tissue allograft accelerates time to continence following robot-assisted radical prostatectomy., Peter A Elliott, Stephanie Hsiang, Ramkishen Narayanan, James Bierylo, Shu-Ching Chang, Przemyslaw Twardowski, and Timothy G Wilson
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer., Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara M Tolaney, and Jennifer K Litton
Enhancing the generation of Eomeshi CD8+ T cells augment the efficacy of OX40- and CTLA-4-targeted immunotherapy., Dana A Emerson, Annah S Rolig, and William L. Redmond
Are There Limits in Explainability of Prognostic Biomarkers? Scrutinizing Biological Utility of Established Signatures., Frank Emmert-Streib, Kalifa Manjang, Matthias Dehmer, Olli Yli-Harja, and Anssi Auvinen
Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer., Miquel Ensenyat-Mendez, Pere Llinàs-Arias, Javier I J Orozco, Sandra Íñiguez-Muñoz, Matthew P Salomon, Borja Sesé, Maggie L DiNome, and Diego M Marzese
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia., Toby A Eyre, Nicole Lamanna, Lindsey E Roeker, Chaitra S Ujjani, Brian T Hill, Paul M Barr, Erick Lansigan, Bruce D Cheson, Maryam Yazdy, John N Allan, Joanna Rhodes, Stephen J Schuster, Chadi Nabhan, Alan Skarbnik, Lori Leslie, Prioty Islam, Katherine Whitaker, Catherine C Coombs, Hande H Tuncer, John M Pagel, Ryan Jacobs, Allison M Winter, Neil Bailey, Andrea Sitlinger, Anna H Schuh, George Follows, Christopher P Fox, Danielle M Brander, Mazyar Shadman, and Anthony R Mato
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study., Toby A Eyre, Anna Schuh, William G Wierda, Jennifer R Brown, Paolo Ghia, John M Pagel, Richard R Furman, Jean Cheung, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Yan Xu, John C Byrd, and Peter Hillmen
Challenges and Errors in Genetic Testing: The Fifth Case Series., Meagan B Farmer, Danielle C Bonadies, Holly J Pederson, Kathryn A Mraz, Julie W Whatley, Deanna R Darnes, Jessica Johnson Denton, Diana De Rosa, Alexis Heatherly, Jessica Kenney, Kimberly Lane, Deborah Paul, Renée C Pelletier, Kristen Shannon, Danielle Williams, and Ellen T Matloff
Challenges and Errors in Genetic Testing: The Fifth Case Series., Meagan B Farmer, Danielle C Bonadies, Holly J Pederson, Kathryn A Mraz, Julie W Whatley, Deanna R Darnes, Jessica Johnson Denton, Diana De Rosa, Alexis Heatherly, Jessica Kenney, Kimberly Lane, Deborah Paul, Renée C Pelletier, Kristen Shannon, Danielle Williams, and Ellen T Matloff
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of, Michael D Farwell, Raymond F Gamache, Hasan Babazada, Matthew D Hellmann, James J Harding, Ron Korn, Alessandro Mascioni, William Le, Ian Wilson, Michael S Gordon, Anna M Wu, Gary A Ulaner, Jedd D Wolchok, Michael A Postow, and Neeta A Pandit-Taskar
NCI Imaging Data Commons., Andrey Fedorov, William J R Longabaugh, David Pot, David A Clunie, Steve Pieper, Hugo J W L Aerts, André Homeyer, Rob Lewis, Afshin Akbarzadeh, Dennis Bontempi, William Clifford, Markus D Herrmann, Henning Höfener, Igor Octaviano, Chad Osborne, Suzanne Paquette, James Petts, Davide Punzo, Madelyn Reyes, Daniela P Schacherer, Mi Tian, George White, Erik Ziegler, Ilya Shmulevich, Todd Pihl, Ulrike Wagner, Keyvan Farahani, and Ron Kikinis
383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695, Pablo Fernandez-Penas, Carmen Ballesteros-Merino, Shawn M. Jensen, Bernard A Fox, and See full list of authors in comments
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials., Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García-Campelo, William Edenfield, Trevor M Feinstein, Jennifer M Johnson, Sujith Kalmadi, Philip E Lammers, Alfredo Sanchez-Hernandez, Yili Pritchett, Shannon R Morris, Rajesh K Malik, and Tibor Csőszi
Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311)., Robert L. Ferris, Yael Flammand, Richard Bryan Bell, and See list of authors in comments
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial., Robert L Ferris, William C Spanos, Rom Leidner, Anthony Gonçalves, Uwe M Martens, Chrisann Kyi, William Sharfman, Christine H Chung, Lot A Devriese, Helene Gauthier, Simon I Chiosea, Lazar Vujanovic, Janis M Taube, Julie E Stein, Jun Li, Bin Li, Tian Chen, Adam Barrows, and Suzanne L Topalian
Associations of practical, emotional, and physical problems with psychosocial distress among cancer patients., Mark William Flanagan, Heather H Goltz, John W Henson, and Matthew Lee Smith
Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors., Corey C Foster, Marcus Couey, Sara E Kochanny, Arun Khattri, Rajesh K Acharya, Yi-Hung Carol Tan, Ryan J Brisson, Rom S Leidner, and Tanguy Y Seiwert
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma., Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A Reeves, Wanda Knopińska-Posłuszny, Chan Y Cheah, Tycel Phillips, Ewa Lech-Maranda, Bruce D Cheson, Paolo F Caimi, Sebastian Grosicki, Lori A Leslie, Julio C Chavez, Gustavo Fonseca, Sunil Babu, Daniel J Hodson, Spencer H Shao, John M Burke, Jeff P Sharman, Jennie Y Law, John M Pagel, Hari P Miskin, Peter Sportelli, Owen A O'Connor, Michael S Weiss, and Pier Luigi Zinzani
Evaluating the cancer surfaceome: a possible strategy to identify targets and monitor immunity, Bernard A Fox
Exploiting Autophagy and the Ubiquitin Pathway to Educate the Immune System and Improve Cancer Immunotherapy, Bernard A Fox
Immunogenic cell death and antigen release, Bernard A Fox
Shared Immunogenic Cancer Antigens in Humans and Combination Immunotherapy Clinical Trials that Exploit Those Antigens, Bernard A Fox
Translation: An Iterative and Team Process – Our Path to the Development of Triplet Cancer Immunotherapy, Bernard A Fox
Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry., Shelby Frantz, Lea Matsuoka, Kirubahara Vaheesan, Michael Petroziello, Jafar Golzarian, Eric Wang, Ripal Gandhi, Zach Collins, Jayson Brower, Varun M Rachakonda, Liping Du, Andrew S Kennedy, Daniel Y Sze, Justin Lee, and Daniel B Brown
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies., Richard R Furman, John C Byrd, Roger G Owen, Susan M O'Brien, Jennifer R Brown, Peter Hillmen, Deborah M Stephens, Nataliya Chernyukhin, Tamara Lezhava, Ahmed M Hamdy, Raquel Izumi, Priti Patel, Marshall Baek, Beth Christian, Martin J S Dyer, Matthew J Streetly, Clare Sun, Simon Rule, Michael Wang, Paolo Ghia, Wojciech Jurczak, John M Pagel, and Jeff P Sharman
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies., Siqing Fu, David E Piccioni, Hongtao Liu, Rimas V Lukas, Santosh Kesari, Dawit Aregawi, David S Hong, Kenichiro Yamaguchi, Kate Whicher, Yi Zhang, Yu-Luan Chen, Nagaraju Poola, John Eddy, and David Blum
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study., Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan, Elena Garralda, Luis G Paz-Ares, Byoung Chul Cho, Shirish M Gadgeel, Michael Thomas, Stephen V Liu, Matthew H Taylor, Aaron S Mansfield, Viola W Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D Turner, and Vivek Subbiah
SGNTGT-001: A phase 1 study of SEA‑TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress)., Elenda Garralda, Rachel E Sanborn, and See list of authors in comments
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients., Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, Natalie S Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C Rossi, Rami Kotb, Darrell White, Nizar J Bahlis, Christine I Chen, Heather J Sutherland, Sumit Madan, Richard LeBlanc, Michael Sebag, Christopher P Venner, William Bensinger, Noa Biran, Sonia Ammu, Osnat Ben-Shahar, Andrew DeCastro, Dane Van Domelen, Tianjun Zhou, Chris Zhang, Ohad S Bentur, Jatin Shah, Sharon Shacham, Michael Kauffman, and Brea Lipe
